Earlier, the company states: “Nektar (NKTR) Therapeutics announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Upcoming Stock Splits This Week (June 9 to June 13) – Stay Invested
- Nektar trading halted, news pending
- Nektar Therapeutics Approves Reverse Stock Split
- Nektar Therapeutics Elects New Board, Approves Key Proposals
- Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics